Latest news and research on all cancers and treatments, updated several times a week, plus 10,000-item data base of these
In the late 1800s, a New York surgeon named William Coley noticed that some patients with cancer seemed to fare better if they developed an ...
The symposium covered fields including organ and composite tissue transplantation, cell transplantation,cancer immunotherapy, immune tolerance ...
Collaborative Education Meetings. I Translational Forum on Cancer Immunotherapy (FIT-Cancer-I). March 13-14, 2015 - Seville, Spain ...
What she was receiving was a drug on the frontier of cancer treatment: those that allow the body's immune system to kill the tumor rather than a ...
This creates a natural target for immunotherapy -- therapy that harnesses the power of a patient's own immune system to help destroy cancer cells, ...
“We need to think about how to schedule chemotherapy in different ways, whether we can use the immune system to tackle cancer as well as drugs, ...
“Unituxin is a new therapy that tricks the body into recognizing the cancer has foreign and attacks it with the tools of the child's own immune system, ...
... in the development of DCVax, a platform technology that uses activated dendritic cells to mobilize a patient's own immune system to attack cancer.
Immunotoxin Effectively Targets B-Cell Malignancies
In a phase I trial, DT2219, the novel bispecific ligand-directed toxin, has shown activity against relapsed and refractory B-cell lymphoma and leukemia.
In a phase I trial, DT2219, the novel bispecific ligand-directed toxin, has shown activity against relapsed and refractory B-cell lymphoma and leukemia.
When Informed of Overdetection, Do Patients Still Want Screening?
The issue of overdetection of cancer from screening must be addressed sooner than later, say experts.
The issue of overdetection of cancer from screening must be addressed sooner than later, say experts.
Adding Bevacizumab to Endocrine Therapy No Help in Advanced Breast Cancer
The addition of bevacizumab to endocrine therapy did not prolong survival in postmenopausal women with advanced HER2-negative, HR–positive breast cancer.
The addition of bevacizumab to endocrine therapy did not prolong survival in postmenopausal women with advanced HER2-negative, HR–positive breast cancer.
Where are we currently in the fight against cancer, one of the leading .... Genetic analysis is also helping to aid in the fight against pancreatic cancer.
Lustgarten.org offers information, advice and support for people and family suffering from cancer of the pancreas.
Recent advances in molecular biology and drug design have described novel targets in bladder cancer. EGFR, fibroblast growth factor receptor ...
This meta-analysis was conducted to assess the association between fruit and vegetable intake and bladder cancer risk. Eligible studies published up ...
For the last 30 years, the standard of care for this disease has consisted of combination chemotherapy with a platinum-containing regimen as first-line ...
BACKGROUND: The purpose of this study was to evaluate the diagnostic accuracy of [18F] fluorodeoxyglucose (FDG) positron emission ...
However, the drug is under trial for multiple additional indications including bladder cancer, head and neck cancer, non small cell lung cancer and ...
... Hospital in Copenhagen found that post MI, patients may be at a higher risk for cancer in general, and for lung and bladder cancer in particular.
... followed by radical cystectomy (arm A), with those treated by radical cystectomy (arm B) in the management of stage II, III urinary bladder cancer.
Bladder cancer is the most common malignancy in urinary system and the ninth most common malignancy in the world. MicroRNAs (miRNAs) are ...
The molecule also seems to play a role in a wide range of cancers. ... to ovarian and breast cancer to prostate and pancreatic cancer," said Copland.
Pancreatectomy—Surgery to remove all or part of the pancreas to treat ... such as benign (non-cancerous) pancreatic tumors, pancreatic cancer and ...
A study that sequenced 100 pancreatic cancer genomes for the first time provides a new understanding of the disease's origin and may help guide ...
Science Daily Cancer News
DT2219, a new bispecific ligand-directed diphtheria toxin, was found to be safe and clinically effective in a small group of patients with relapsed/refractory B-cell malignancies, according to phase I clinical trial data.
A new genome editing technology has been developed that can target and kill blood cancer cells with high accuracy. Using the technology, researchers were able to kill human lymphoma cells by locating and deleting an essential gene for cancer cell survival.
Tambahkan Komentar